Introduction
============

*BRCA2*, since its discovery as a breast cancer susceptibility gene \[[@B1]\], has been implicated in processes fundamental to all cells, including proliferation \[[@B2]\], development \[[@B3],[@B4]\], DNA repair \[[@B5],[@B6]\], transcription \[[@B7]\], and centrosome duplication \[[@B8]\]. Consistent with the tumor suppressor status of the gene, tumors that develop in carriers of heterozygous *BRCA2*mutations are frequently associated with loss of heterozygosity at the *BRCA2*locus \[[@B9]\]. Inherited mutations in the gene continue to be associated with the familial form of breast, ovarian, and other types of cancer \[[@B10],[@B11]\], which represent only a small proportion of the total cases. The role of *BRCA2*in the development of the sporadic form of breast cancer remains undefined. Although loss of heterozygosity of the *BRCA2*locus has been detected in more than 50% of sporadic breast tumors \[[@B12]\], somatic mutations \[[@B13]-[@B15]\] or inactivation by methylation has been either absent or rare \[[@B16]\]. The involvement of altered expression of *BRCA2*in the development of sporadic breast cancer is a possibility.

*BRCA2*gene expression, owing to its functional relevance, is tightly regulated by several known and unknown factors, which in turn could be candidates responsible for the deregulated expression of *BRCA2*, thus leading to cancer. Its expression is elevated indirectly in response to the mitogenic activity of estrogen, which has been associated with progression of the cell cycle \[[@B3]\]. Cell cycle-dependent expression has been associated with binding of the upstream stimulatory factor protein and EIf-1 transcription factor to the *BRCA2*promoter \[[@B17]\]. Wu and colleagues \[[@B18]\] provided evidence for direct induction of the *BRCA2*promoter through binding of nuclear factor-kappa B. *BRCA2*shares a complex regulatory loop with *p53*that may be directly associated with the cellular response to DNA damage. *BRCA2*limits the length or severity of the *p53*-mediated cell cycle-arrest phenotype by inhibiting transactivation activity of *p53*\[[@B4],[@B19],[@B20]\], and *p53*represses *BRCA2*expression in response to genotoxic stress \[[@B21]\].

Thus, polymorphisms in the regulatory region of the *BRCA2*gene, which can modulate the fine-tuned regulation of its expression, are logical candidates to provide risk for breast cancer. In the present study, we ascertain the functional role of a common polymorphism -26 G\>A (GenBank accession number [AY151039](AY151039), rs1799943) in the 5\' untranslated region (UTR) of the *BRCA2*gene and test its implications in breast cancer pathogenesis. Furthermore, it has been hypothesized that breast cancer is a complex disease and that variants in multiple biologically related genes combine to affect the risk. In light of the fact that there is a functional interaction between *BRCA2*and *p53*in the DNA damage response pathway, the status of the widely studied *p53*codon 72 Arg/Pro polymorphism \[[@B22]-[@B41]\] and its interaction with -26 *BRCA2*polymorphism was also evaluated.

Materials and methods
=====================

Cloning of *BRCA2*promoter + 5\' UTR
------------------------------------

The minimal promoter of *BRCA2*and the 5\' UTR with A or G at the -26 position (HUGO nomenclature) was amplified from already genotyped healthy control DNA, using the following primers: forward 5\'-GATACTGACGGTTGGGATG-3\' and reverse 5\'-ATTTTTACCTACGATATTCCT-3\' with long polymerase chain reaction (PCR) enzyme mix (Fermentas Canada Inc., Burlington, ON, Canada). The amplified product was cloned in TOPO cloning vector (Invitrogen Corporation, Carlsbad, CA, USA). It was then digested with Kpn and XhoI (Fermentas Canada Inc.) for cloning into pGL3 basic vector (Promega Corporation, Madison, WI, USA). Sequencing (Applied Biosystems, Foster City, CA, USA) was performed to confirm positive clones and the change at -26 5\' UTR.

Cell culture
------------

Human breast adenocarcinoma MCF-7 and cervical carcinoma HeLa cells were propagated in Dulbecco\'s modified Eagle\'s medium (DMEM) supplemented with 10% bovine calf serum and maintained at 37°C with 5% CO~2~(cell culture reagents were obtained from Life Technologies, Inc., now part of Invitrogen Corporation).

Transient transfection and luciferase assays
--------------------------------------------

Plasmid DNA was isolated using the plasmid maxi kit (Qiagen Inc., Valencia, CA, USA) for transient transfection. MCF-7 and HeLa cells were plated at a density of 1 × 10^5^cells per well in six-well plates and grown in DMEM with 10% bovine calf serum overnight, prior to transfection. All transfections were carried out using PolyFect (Qiagen Inc.) according to the manufacturer\'s instructions. A total of 1 μg of *BRCA2*promoter construct and 0.1 μg of pRL-TK *Renilla*luciferase vector (Promega Corporation) with 5 μL of PolyFect were used for each transfection. The pRL-TK *Renilla*luciferase activity was used as a control for transfection efficiency. Each transfection experiment was performed in duplicate and repeated a minimum of three times. Firefly luciferase and *Renilla*luciferase assays were performed using the Dual-Luciferase Reporter Assay System (Promega Corporation). Approximately 48 hours after transfection, cells were washed twice with 1× phosphate-buffered saline and harvested with 600 μL of passive lysis buffer (Promega Corporation). Cell lysates were cleared by centrifugation, and 5 μL was added to 100 μL of firefly luciferase substrate, and light units were measured in a luminometer (TD-20/20, DLReady; Turner Designs, Inc., Sunnyvale, CA, USA, and Promega Corporation). *Renilla*luciferase activities were measured in the same tube after addition of 100 μL of Stop and Glo reagent. For adriamycin (ADR) (Sigma-Aldrich, St. Louis, MO, USA) treatment experiments, MCF-7 and HeLa cells were transfected, grown for 24 hours, and exposed to 0, 1, and 2.5 μM ADR for 1 hour in standard medium. The cells were washed with serum-free medium and incubated at 37°C in fresh culture medium for another 24 hours before harvesting for luciferase assay.

Cases and controls
------------------

A total of 576 peripheral blood samples from north India were studied for the germline status of polymorphisms in the 5\' UTR of *BRCA2*and codon 72 of the *p53*gene. This included 243 patients with sporadic breast cancer and 333 unrelated, healthy female controls with no history of breast cancer. In 145 of the 243 patients, tumors along with corresponding blood samples and adjacent normal tissues (only in 5 cases in which blood sample was not available) were also obtained to assess the somatic status of the mentioned amplified regions and genomic instability for the informative markers (mentioned below) established over a period of time in our laboratory in a pair study. Care was taken that both cases and controls were ethnically and geographically matched. Prior approval was given by the Jawaharlal Nehru University ethical committee and the concerned subjects for sample collection and study. The tissue samples were frozen immediately after collection and stored at -80°C until use. DNA was extracted from the peripheral blood leucocytes and from tissues according to the standard phenol-chloroform method.

Polymorphism study
------------------

PCR was performed under conditions similar to those described earlier \[[@B42]\] with the following primer sequences (respective annealing temperatures are mentioned alongside): -26G\>A polymorphism in *BRCA2*, forward 5\'-CTC AGT CAC ATA ATA AGG AAT-3\' and reverse 5\'-ACA CTG TGA CGT ACT GGG TTT T-3\' (55°C) and exon 4 codon 72 Arg\>Pro polymorphism, forward 5\'-TGC TCT TTT CAC CCA TCT AC-3\' and reverse 5\'-ATA CGG CCA GGC ATT GAA GT-3\' (62°C). Thereafter, polymorphisms were detected by sequencing of their respective PCR products.

Genomic instability analysis
----------------------------

Mutation analysis of exons 5 to 8 of the *p53*gene and allelic imbalance study using three informative markers each in chromosome 16 (D16S3082, D16S423, and D16S413) and chromosome 17 (D17S379, D17S934, and D17S787) were carried out according to the procedure mentioned earlier \[[@B42]\] in 145 of 243 paired samples.

Statistical analysis
--------------------

First, overall genotype frequencies of breast cancer patients and control subjects were compared using the 3 × 2 chi-square test. Once a significant overall difference between patients and controls subjects was detected (*P*\< 0.05), the individual genotypes were analyzed using an unconditional logistic regression model with correction for age using the SPSS statistical package, version 10 (SPSS Inc., Chicago, IL, USA). To compare the relative luciferase activity and the genomic instability analysis, the *t*test and the chi-square/Fisher exact test were used, respectively \[[@B43]\]. Statistical significance was considered at a *P*value of less than or equal to 0.05.

Results
=======

Effect of 5\' UTR -26 G\>A polymorphism on reporter gene expression
-------------------------------------------------------------------

To study the effect on expression of *BRCA2*5\' UTR -26 G\>A polymorphism, HeLa and MCF-7 cells were transiently transfected with reporter gene construct (pGL3Basic) with A or G at the polymorphic site. Figure [1](#F1){ref-type="fig"} (upper panel) shows how the construct containing the A allele showed significantly higher expression than the one with the G allele in HeLa (*P*= 0.013) as well as MCF-7 (*P*= 0.003) cell lines. Both HeLa and MCF-7 cells exposed to various concentrations of ADR for 1 hour after 24 hours of transfection downregulated the overall expression as expected, but the trend of A allele expressing higher than its alternative G allelic form was maintained (Figure [1](#F1){ref-type="fig"}, lower panel). The increased activation of *p53*by ADR treatment was observed in our experiments as well (data not shown).

![Reporter gene assay with chimeric *BRCA2*promoter and 5\' untranslated region (UTR) with A or G at the -26 position (upper panel) and the effect of increasing the dose of adriamycin (0, 1, and 2.5 μM) (lower panel).](bcr1780-1){#F1}

Computational assessment of the regulation of *BRCA2*expression by -26 G\>A polymorphism
----------------------------------------------------------------------------------------

The analysis of the polymorphic region for the presence of a putative transcription factor binding site by means of the AliBaba 2.1 program \[[@B44]\] revealed that the G\>A change creates a C/EBP alpha (TTTACCAA[G]{.ul}C \> TTTACCAA[A]{.ul}C) binding site. The presence of an OCT1 binding site almost overlapping to this region, however, was not affected by the polymorphism. The analysis of the complete 5\' UTR with G or A at the -26 position for RNA secondary structure folding by RNAstructure program (version 4.3) \[[@B45]\] depicted a 40-base pair (bp) loop formation in the vicinity of the translation start site and this structure changed with the change of the G\>A base at the position. Furthermore, RNA secondary structure folding of the 40-bp loop with free energy change (ΔG) calculation, when compared using two different programs, showed a similar trend in the results obtained. The base substitution brought a change in the structure, and the presence of G at the -26 position significantly increased ΔG (-9.4 kcal/mole versus -5.1 kcal/mole by RNAstructure V4.3 and -10.46 kcal/mole versus -7.10 kcal/mole by VRNAAFOLD, The European Molecular Biology Open Software Suite) \[[@B46]\] when compared with that of the A allele at the same position (Figure [2](#F2){ref-type="fig"}).

![Effect of -26 G/A polymorphism on the 5\' untranslated region secondary structure of RNA and stability analyzed by the RNAstructure program (version 4.3) and VRNAAFOLD (The European Molecular Biology Open Software Suite). The -26 position with G or A is indicated by arrows.](bcr1780-2){#F2}

5\' UTR -26 G\>A polymorphism in association with breast cancer risk
--------------------------------------------------------------------

To further assess the relevance of this functional polymorphism, a preliminary case-control study was undertaken to assess the effect of -26 G\>A on sporadic breast cancer susceptibility. Table [1](#T1){ref-type="table"} presents the details of the genotype and allele frequencies along with the risk calculations. The overall distribution of genotype frequencies between patients and controls was found to be significant (*P*= 0.001). Surprisingly, the heterozygous genotype provided approximately twice the protection than the common G/G homozygous state (*P*~heterozygote\ advantage\ model~= 0.0005, odds ratio \[OR\] = 0.5, 95% confidence interval \[CI\] = 0.4 to 0.8). However, there was no significant difference in the distribution of the A/A homozygous genotype in comparison with the G/G homozygous state (*P*= 0.677, OR = 1.1, 95% CI = 0.6 to 2.1) and the allele frequencies (*P*= 0.092).

###### 

Genotype and allele frequencies of *BRCA2*-26 and *p53*codon 72 polymorphisms in sporadic breast cancer patients and normal controls

  Genotypes                          Patients      Controls      *P*^a^         *P*^b^   *P*^c^      OR (95% CI)^d^
  ---------------------------------- ------------- ------------- -------------- -------- ----------- ----------------
                                     *N*= 243      *N*= 333                                          
                                                                                                     
  *BRCA2*, exon 2, -26G\>A                                                                           
   G/G                               144 (59.3%)   157 (47.1%)                           \-          1.0 (referent)
   G/A                               74 (30.5%)    152 (45.6%)                           0.0005^e^   0.5 (0.4--0.8)
   A/A                               25 (10.3%)    24 (7.2%)     0.002, 0.116   0.001    0.677       1.1 (0.6--2.1)
   G                                 74.50%        70.00%                                0.092       1.2 (1.0--1.6)
  *p53*, exon 4, codon 72 Arg\>Pro                                                                   
   Pro/Pro                           48 (19.8%)    97 (29.1%)                            \-          1.0 (referent)
   Pro/Arg                           109 (44.9%)   160 (48.0%)                           0.119       1.4 (0.9--2.1)
   Arg/Arg                           86 (35.4%)    76 (22.8%)    0.210, 0.521   0.001    0.0005^e^   2.3 (1.4--3.6)
   Pro                               42.20%        53.20%                                0.0002^e^   0.6 (0.5--0.8)

^a^*P*value for Hardy-Weinberg equilibrium testing. ^b^*P*value for 3 × 2 chi-square test of comparison of overall genotype frequencies between breast cancer patients and controls. ^c,d^*P*values and corresponding age-adjusted ORs with 95% CIs for comparison of genotype frequencies between breast cancer patients and controls by logistic regression (not adjusted for age in allele frequency comparisons); the referent genotypes were considered on the basis of highest proportion of a homozygous genotype at any particular locus in the control group. ^e^*P*values continue to remain significant after applying Bonferroni correction of 2 (2 single-nucleotide polymorphisms tested in a case-control group) to correct for multiple comparisons. CI, confidence interval; OR, odds ratio.

Heterozygous genotype in association with genomic instability
-------------------------------------------------------------

To test the hypothesis that the *BRCA2*heterozygous genotype provides protection in comparison with either of the homozygous genotypes at the -26 position in the 5\' UTR, allelic imbalance for the selected informative markers in chromosomes 16 and 17 was studied along with mutation in the *p53*gene (mutation details provided in Additional File [1](#S1){ref-type="supplementary-material"}) in a panel of normal and tumor tissues already characterized for the polymorphism. Interestingly, the tumors with a heterozygous background for the polymorphism showed a decreased frequency of allelic imbalance for the three informative markers each on chromosomes 16 and 17 as well as *p53*somatic mutations when compared with either of the homozygous tumors (Figure [3](#F3){ref-type="fig"}). Further delineation of genotype comparisons showed that GG versus GA (*P*= 0.038, *P*= 0.009) was significant compared with AA versus GA (*P*= 0.771, *P*= 0.129) for allelic imbalance in chromosomes 16 and 17, respectively. Inversely, AA versus GA (*P*= 0.076) showed a nonsignificant trend toward association compared with GG versus GA (*P*= 0.613) when *p53*somatic mutations were compared. Incidentally, both the 5\' UTR of *BRCA2*and exon 4 of the *p53*gene did not show any somatic variation in tumor tissues of the studied samples.

![Comparison of allelic imbalance in chromosomes 16 and 17 along with mutation in *p53*with -26 G\>A polymorphism background. *P*values given are for overall distribution, G/G versus G/A, and A/A versus G/A.](bcr1780-3){#F3}

Status of *p53*codon 72 Arg/Pro polymorphism and its interaction with *BRCA2 -26*polymorphism
---------------------------------------------------------------------------------------------

The overall genotype frequency distribution at the codon 72 locus between patients and controls was found to be significantly different (*P*= 0.001). The *p53*codon 72 Arg homozygous genotype (*P*= 0.0005, OR = 2.3, 95% CI = 1.4 to 3.6) as well as the Arg allele (*P*~allele\ model~= 0.0002, OR = 1.7, 95% CI = 1.2 to 2.0) were significantly over-represented in patients (Table [1](#T1){ref-type="table"}). Stratified genotypic data to assess the combined influence of both *p53*and *BRCA2*polymorphisms on breast cancer risk revealed that the G/A at the -26 position of *BRCA2*in combination with the Pro allele at the codon 72 locus provided fivefold protection against breast cancer (*P*= 0.0001, OR = 0.2, 95% CI = 0.1 to 0.4) (Table [2](#T2){ref-type="table"}).

###### 

Interaction between the polymorphisms: *p53*codon 72 and *BRCA2*-26 in sporadic breast cancer patients and normal controls

  Genotypic combination   Patients   Controls                                
  ----------------------- ---------- ------------- ------------- ----------- -----------------
  Pro/Pro                 G/G        38 (15.63%)   45 (13.51%)   \-          1 (referent)
  Pro/Pro                 G/A        7 (2.88%)     46 (13.81%)   0.0002^c^   0.2 (0.1--0.4)
  Pro/Pro                 A/A        3 (1.23%)     6 (1.80%)     0.476       0.6 (0.1--2.5)
  Pro/Arg                 G/G        59 (24.27%)   78 (23.42%)   0.686       0.9 (0.5--1.5)
  Pro/Arg                 G/A        38 (15.64%)   68 (20.42%)   0.166       0.7 (0.4--1.2)
  Pro/Arg                 A/A        12 (4.94%)    14 (4.20%)    0.983       1.0 (0.4--2.4)
  Arg/Arg                 G/G        47 (19.34%)   34 (10.21%)   0.120       1.6 (0.9--3.0)
  Arg/Arg                 G/A        29 (11.93%)   38 (11.41%)   0.754       0.9 (0.5--1.7)
  Arg/Arg                 A/A        10 (4.11%)    4 (1.20%)     0.087       3.0 (0.9--10.2)

^a,b^*P*values and corresponding age-adjusted ORs with 95% CIs for comparison of combination of genotype frequencies between breast cancer patients and controls by logistic regression. ^c^*P*values continue to remain significant after applying Bonferroni correction of 9 (9 combinations tested in a case-control group) to correct for multiple comparisons. CI, confidence interval; OR, odds ratio.

Discussion
==========

The failure of mutational inactivation of the *BRCA2*gene to show an association with breast cancer, specifically the sporadic form, in two recent reports from India \[[@B14],[@B15]\] indicated the need to further explore the involvement of *BRCA2*in breast cancer susceptibility, with altered expression as a possibility. We propose that -26 G\>A polymorphism in the 5\' UTR of *BRCA2*has a regulatory role and acts as one of the risk factors, modulating the function of *BRCA2*in breast cancer pathogenesis, further influenced by codon 72 polymorphism in the *p53*gene.

The functional characterization of the common G\>A polymorphism in the *BRCA2*-26 5\' UTR by reporter assay revealed that the A allele led to higher expression than the G allele in both HeLa and MCF-7 cell lines. This suggests that the polymorphism might have a role in the regulation of *BRCA2*expression. Upholding the same trend by ADR treatment further implied that the -26 polymorphism might regulate *BRCA2*expression independent of other factors, specifically to the repression of the *BRCA2*promoter by ADR via *p53*activation \[[@B21]\]. A search for a consensus sequence for the putative transcription factor in the polymorphic site revealed the creation of a C/EBP alpha transcription binding site by the change from G\>A in the -26 polymorphic position. However, the presence of an OCT1 binding site almost overlapping to this region, not affected by the polymorphism, makes the transcriptional control hypothesis an unlikely one, unless proven by the gel shift or chromatin immunoprecipitation assays. The analysis of the 5\' UTR for the RNA secondary structure by two different programs showed that the presence of G at -26 stabilized the loop at the vicinity of the translation start site, which could decrease the efficiency of the translation and thereby decrease the expression of *BRCA2*. This finding of ours is supported by the classic work of Vega Laso and colleagues \[[@B47]\] and Kozak \[[@B48]\], who have argued that the extent of a hairpin negative effect on eukaryotic mRNA translation *in vivo*depends upon its stability and localization within the molecule.

The -26 G\>A polymorphism in the 5\' UTR of *BRCA2*has been analyzed in some cancer types. In one study, the -26A allele was reported to show a borderline association with ovarian cancer, but similar results in breast cancer with *BRCA1*mutation carriers were not found \[[@B49]\]. Another study showed a monotonic increase in the frequency of the heterozygous G/A genotype from the lowest to highest risk groups of esophageal squamous cell carcinoma from northern China \[[@B50]\]. Our observation supports a heterozygote-protective model, which has been well recognized in infectious diseases \[[@B51]\] and is consistent with the initial findings of Healey and colleagues \[[@B52]\] in sporadic breast cancer. An increased genomic instability in the homozygotes compared to heterozygotes substantiates the protective nature of the heterozygous genotype. The differential results of the association study as reported previously could be due to the outcome of various single-nucleotide polymorphism (SNP)--SNP and SNP--environment interactions, again modulated by population and disease type. Nevertheless, our observations of the A allele associated with higher expression and increased genomic instability via inhibition of *p53*transactivation \[[@B4],[@B19],[@B20]\] and of the G allele with low expression impairing the DNA repair leading to genomic instability \[[@B53]-[@B55]\] apparently explain the risk provided by the homozygous state of the two alleles A and G to breast cancer. Our results also showed that either of the homozygous forms is associated with increased allelic imbalance or *p53*mutations, which again is in line with the findings on consequences of aberrant expression of *BRCA2*\[[@B4],[@B19],[@B20],[@B53]-[@B55]\]. On the basis of these observations, it seems apparent that a germline heterozygosity status at -26 5\' UTR may therefore confer a protective phenotype characterized by intermediate levels of *BRCA2*expression and an optimal balanced DNA damage response, specifically to double-strand breaks.

To test the SNP--SNP interaction model, functional polymorphism at codon 72 of *p53*was considered based on the emerging hypothesis that variants in many genes along related biological pathways combine to influence breast cancer risk. The two alleles of the Arg72Pro polymorphism of *p53*differ in their biological activities. The Pro allele is associated with increased transcription of *p53*target genes via greater binding to transcriptional machinery and thus shows higher rates of G~1~arrest than the Arg allele \[[@B22]\]. In contrast, the Pro allele is less efficient in suppressing transformation (likely due to reduced apoptotic potential) than the Arg allele \[[@B22]-[@B24]\], which could be due to efficient binding and regulation by iASPP (inhibitory member of the ASPP family) \[[@B25]\]. A summary of case-control reports on the association of codon 72 polymorphism with breast cancer across the globe, including our results, revealed an inconsistency in association \[[@B26]-[@B41]\], again pointing toward modulations by multiple factors (Additional File [2](#S2){ref-type="supplementary-material"}). Our analysis of the interaction between -26 *BRCA2*and codon 72 *p53*polymorphism showed that the simultaneous presence of protective genotypes, Pro/Pro at the *p53*codon 72 locus and G/A at the -26 *BRCA2*locus, rendered fivefold protection against breast cancer and was approximately twice of what each genotype rendered alone.

Conclusion
==========

Our study shows that 5\' UTR -26 polymorphism of *BRCA2*might regulate its expression, albeit not at a transcriptional level, but at a post-transcriptional level affecting the translational efficiency. It is interesting to presume that the low-penetrating SNP can modulate the fine-tuned regulation of the multifunctional gene *BRCA2*, leading to the differential form of genomic instability and rendering risk to the sporadic form of breast cancer. This also provides an alternative to the involvement of *BRCA2*in the sporadic form in which inactivation by somatic mutagenesis and methylation is known to be rare. The analysis also puts into perspective the functional implication of the dimorphic germline status of *p53*in the background of 5\' UTR of *BRCA2*in sporadic breast cancer development and calls for more of such studies in humans to understand the epistatic effect of genetic backgrounds in the promotion and progression of the cancer.
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